Adverum Biotechnologies, Inc.

ADVM

US00773U2078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
6.89 ^USD	-3.37%		+0.44%	-8.48%

07-01	Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Small Cap Comp Value Index	CI
07-01	Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Small Cap Completeness Index	CI

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Small Cap Comp Value Index

July 30, 2024

Latest news about Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Small Cap Comp Value Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Small Cap Completeness Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 3000 Value Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 2000 Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 3000E Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Microcap Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 2500 Value Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 2000 Value Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 2000 Dynamic Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell Microcap Value Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 2500 Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 3000 Index	06-30	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) added to Russell 3000E Value Index	06-30	CI
Oppenheimer Initiates Coverage on Adverum Biotechnologies With Outperform Rating, $25 Price Target	06-25	MT
Adverum Biotechnologies, Inc. Announces Executive Changes	06-11	CI
Transcript : Adverum Biotechnologies, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM	05-15
Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target	04-30	MT
Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating	04-29	MT
Adverum Biotechnologies Files $200 Million Mixed Shelf	03-21	MT
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk	03-19	MT
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-18	CI
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	02-20	CI
Transcript : Adverum Biotechnologies, Inc. - Special Call	02-08

Chart Adverum Biotechnologies, Inc.

Duration

Period

More charts

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Sector

Biotechnology & Medical Research

Calendar

2024-07-17 - American Society of Retina Specialists Scientific Meeting - Wet AMD Symposium 1

More about the company

Income Statement Evolution

More financial data

Ratings for Adverum Biotechnologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.89 USD

Average target price

33.86 USD

Spread / Average Target

+391.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADVERUM BIOTECHNOLOGIES, INC.	-8.48%	143M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs